Identification of Novel Predictive Biomarkers for Endometrial Malignancies: N -Acylethanolamines

• Published in: Frontiers in oncology 2019-06, Vol.9, p.430-430
• Main Authors: Ayakannu, Thangesweran, Taylor, Anthony H, Marczylo, Timothy H, Maccarrone, Mauro, Konje, Justin C
• Format: Article
• Language: English
• Subjects: anandamide; biomarker; endocannabinoid; endometrial cancer; Oncology; prediction
• ISSN: 2234-943X; 2234-943X
• DOI: 10.3389/fonc.2019.00430

To identify new biochemical markers for endometrial cancer (EC). Recent evidence suggests that members of the endocannabinoid system ( -acylethanolamines) that bind to and activate receptors that are dysregulated in EC are involved in this tumour's biology. These observations suggest increased -acylethanolamine levels in the tissue that might appear in plasma and could be used as disease biomarkers. -arachidonoylethanolamine (anandamide, AEA) and the -acylethanolamine substances, -oleoylethanolamine (OEA), and -palmitoylethanolamine (PEA) were quantified in plasma and endometrial tissue collected from 31 EC and seven atrophic controls using UHPLC-MS/MS. Receiver-operating characteristics (ROC) and logistic regression were used to determine diagnostic accuracy. Cannabinoid receptor 1 (CB1) and 2 (CB2) protein levels were determined by specific immunohistochemistry and histomorphometric analyses. Correlations between plasma and tissue levels of the three -acylethanolamines and tissue levels of the three -acylethanolamines and CB1 and CB2 receptor expression levels were determined using correlation analysis. Plasma and tissue AEA and PEA levels were significantly ( < 0.05) higher in EC than controls whilst OEA levels were significantly elevated in type 1 EC tissues but not in plasma. There were significant positive correlations between plasma and tissue levels of AEA ( = 0.302, = 0.008) and PEA ( = 0.182, = 0.047), but not for OEA ( = 0.022, = 0.506). The diagnostic accuracies for EC were: sensitivity of 53.3%, specificity of 100% for plasma AEA (>1.36 nM); sensitivity of 73.3%, specificity of 100% for plasma PEA (>27.5 nM); and sensitivity of 93.3%, specificity of 28.6% for plasma OEA (>4.97 nM). Logistic regression increased the area under the ROC curve (AUC) from 0.781 for AEA, 0.857 for PEA, and 0.543 for OEA to a combined AUC of 0.933 for EC diagnosis. Significant inverse correlations between tissue AEA ( = 0.343, = 0.003) and PEA ( = 0.384, < 0.0001) levels and CB1 expression were observed. No correlation between tissue levels of OEA and CB1 and tissue levels of any of the three -acylethanolamines and CB2 protein expression were observed, except in the type 1 EC patients. Since plasma AEA and PEA are significantly elevated in patients with EC and a reflection of production by the endometrial tumour, then these lipids have the potential to be useful biomarkers for the early diagnosis of EC.